Infectious Disease in Pregnancy

Fifth Disease and Pregnancy: Risks, Screening, and Fetal Monitoring

Fifth Disease, or Erythema Infectiosum, is a common childhood viral illness caused by **Human Parvovirus B19**. While generally mild and self-limiting in children, infection during pregnancy carries specific, rare risks due to the virus targeting red blood cell precursors. For pregnant individuals who are not already immune, exposure, particularly during the first half of gestation, requires proactive monitoring and diagnostic testing. This detailed guide clarifies the mechanism of risk, outlines the necessary serology testing, and details the non-invasive ultrasound surveillance used to ensure fetal well-being.

Understanding Infection and Transmission

Parvovirus B19 spreads through respiratory secretions (coughing, sneezing) and hand-to-mouth contact, common routes in childcare and school settings. Once an individual has had Fifth Disease, immunity is generally lifelong.

Susceptibility and Outbreaks

• Immunity: Approximately 65 percent of adults in the US already possess protective antibodies (IgG) against Parvovirus B19. Individuals without these antibodies are susceptible to infection.
• Risk Factors: Pregnant individuals who work in schools, daycares, or whose children are in school settings face a higher risk of exposure, particularly during community outbreaks, which tend to occur in cycles every three to five years.
• Contagious Period: The infected person is most contagious **before** the typical rash appears. Once the rash or joint pain begins, the infectious window has largely passed.

Maternal Symptoms and Asymptomatic Infection

In adults, Fifth Disease often presents differently than the classic "slapped cheek" rash seen in children, and a large proportion of infections are entirely unnoticed.

Symptoms in Adults and Pregnant Individuals

• Joint Pain (Polyarthropathy): This is the most common symptom in adults, especially women. It presents as pain, stiffness, and swelling, often affecting the hands, wrists, knees, and ankles, and can last for several weeks.
• Flu-Like Prodrome: Initial symptoms are non-specific, such as low-grade fever, headache, fatigue, and malaise.
• Asymptomatic Cases: Between 30 and 50 percent of pregnant individuals who contract the virus experience no symptoms at all, making clinical suspicion based on exposure the primary indicator for testing.

The Specific Fetal Risks of Parvovirus B19

If maternal infection occurs, the virus can cross the placenta (vertical transmission) in about 33 percent of cases. When fetal infection occurs, the primary risk is severe anemia.

The Mechanism: Fetal Anemia and Hydrops Fetalis

Parvovirus B19 preferentially attacks and destroys **erythroid progenitor cells** in the fetal bone marrow. These are the cells responsible for producing red blood cells.

• Severe Anemia: The lack of red blood cells causes severe fetal anemia, reducing the oxygen-carrying capacity of the blood.
• Hydrops Fetalis: To compensate for anemia, the fetal heart works harder (high-output cardiac failure). This strain, combined with damage to the fetal liver, leads to a life-threatening accumulation of fluid in multiple body compartments (skin, abdomen, chest), known as non-immune hydrops fetalis.

The overall risk of a severe complication (hydrops or fetal loss) is low, approximately 2 to 6 percent following maternal infection, but the risk is highly dependent on gestational age.

Diagnostic Screening: Serology and Immunity

Diagnosis relies entirely on maternal blood tests to determine immune status and the timing of the infection relative to the pregnancy.

Interpreting Serology Tests (IgG and IgM)

If a pregnant individual reports exposure, the provider immediately tests for two types of antibodies: IgG and IgM.

Fetal Surveillance and Management Protocols

If acute infection is confirmed in a susceptible pregnant patient, monitoring focuses on non-invasively detecting fetal anemia.

Middle Cerebral Artery Doppler (MCA-PSV)

The gold standard for monitoring fetal anemia is the **Middle Cerebral Artery Peak Systolic Velocity (MCA-PSV)** Doppler ultrasound measurement.

• Mechanism: Anemia causes fetal blood viscosity to decrease. The blood moves faster, resulting in a higher PSV reading in the MCA.
• Protocol: If maternal infection is confirmed, serial MCA-PSV scans are performed, usually every two weeks for a period of 8 to 12 weeks, covering the peak risk window.

Intervention for Severe Anemia

If the MCA-PSV reading exceeds a critical threshold (usually 1.5 Multiples of the Median or MoM), indicating severe fetal anemia or hydrops, the patient is referred to a Maternal-Fetal Medicine (MFM) specialist.

• Intrauterine Transfusion (IUT): The definitive treatment is a fetal blood transfusion, performed in utero via cordocentesis (sampling blood from the umbilical cord). This procedure is highly effective, with success rates often exceeding 80 percent in specialized centers.

Prevention and Exposure Management

There is currently no vaccine against Parvovirus B19. Prevention relies on basic hygiene and managing occupational risk.

Core Prevention Strategies

• Hand Hygiene: Regular, thorough washing of hands, especially after contact with young children and before eating.
• Avoidance: If working in a school or daycare during a known outbreak and the pregnant individual is not immune, minimizing close, sustained contact with children who have a rash or flu-like symptoms is advisable.

Fifth Disease during pregnancy carries a low but serious risk of fetal complication. By establishing baseline immunity early in prenatal care and utilizing prompt serology testing and non-invasive MCA-PSV monitoring after exposure, adverse outcomes can be proactively identified and treated, resulting in a favorable prognosis for the majority of affected pregnancies.